minoxidil
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia
Conditions
Androgenetic Alopecia
Trial Timeline
Oct 1, 2003 → Jul 1, 2004
NCT ID
NCT00151515About minoxidil
minoxidil is a phase 3 stage product being developed by Johnson & Johnson for Androgenetic Alopecia. The current trial status is completed. This product is registered under clinical trial identifier NCT00151515. Target conditions include Androgenetic Alopecia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00151515 | Phase 3 | Completed |
Competing Products
12 competing products in Androgenetic Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 20 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| VDPHL01 | Veradermics | Phase 2 | 47 |
| VDPHL01 QD + Placebo + VDPHL01 BID + Placebo | Veradermics | Phase 3 | 72 |
| VDPHL01 + Placebo | Veradermics | Phase 2/3 | 60 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 72 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Organon | Phase 3 | 72 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 33 |
| ATI-50002 | Aclaris Therapeutics | Phase 2 | 44 |